Israel’s Pharma Two B (see here previously) is presenting the full results of its Phase 3 trial of its once-a-day injection of its P2B001 treatment for Parkinson’s disease. P2B001 combines low-dose pramipexole with low-dose rasagiline. It relieves PD symptoms with … Continue reading →

Israel’s Pharma Two B (see here in 2015) has successfully completed the Phase 3 human trial of its P2B001 treatment for Parkinson’s Disease. The trial met its primary and key secondary endpoints, and the company can now prepare for US … Continue reading →

Israeli biotech Pharma Two B has announced positive results in its Phase IIb pivotal clinical study of P2B001 for the treatment of early stage Parkinson’s disease. The tests combined two low dose chemicals that separately had limited effect and were … Continue reading →